{"id":69112,"date":"2026-06-30T15:18:49","date_gmt":"2026-06-30T07:18:49","guid":{"rendered":"https:\/\/flcube.com\/?p=69112"},"modified":"2026-06-30T15:18:49","modified_gmt":"2026-06-30T07:18:49","slug":"metis-techbio-signs-record-1-62b-global-licensing-deal-for-ai-designed-tri-specific-tce-mts-128-largest-preclinical-tce-out-licensing-by-chinese-pharma-company","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69112","title":{"rendered":"METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 \u2013 Largest Preclinical TCE Out-Licensing by Chinese Pharma Company"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>METiS TechBio<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/7666:HKG\">HKG: 7666<\/a>) announced an exclusive global licensing agreement with <strong>Boulevard Bio<\/strong>, a U.S. biotechnology company backed by <strong>Deerfield Management<\/strong>, granting Boulevard Bio worldwide rights to develop, manufacture, and commercialize <strong>MTS-128<\/strong>, METiS&#8217; self-developed <strong>tri-specific T Cell Engager (TCE)<\/strong> powered by its proprietary <strong>AI-driven NanoForge platform<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-transaction-overview\" class=\"wp-block-heading\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensors<\/strong><\/td><td>METiS TechBio (HKG: 7666)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Boulevard Bio (Deerfield-backed U.S. biotech)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>MTS-128 tri-specific T Cell Engager (TCE)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Global (exclusive)<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 20 million<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to USD 1.6 billion (development, regulatory, commercialization)<\/td><\/tr><tr><td><strong>Additional Consideration<\/strong><\/td><td>Tiered royalties on net sales<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td>USD 1.62 billion + royalties<\/td><\/tr><tr><td><strong>Strategic Significance<\/strong><\/td><td>Largest preclinical TCE out-licensing deal by Chinese pharmaceutical company<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-asset-profile-mts-128-tri-specific-tce\" class=\"wp-block-heading\">Asset Profile: MTS-128 Tri-Specific TCE<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Platform<\/strong>: Proprietary NanoForge AI-driven molecular engineering platform<\/li>\n\n\n\n<li><strong>Development Approach<\/strong>: End-to-end R&amp;D from molecular design to optimization using artificial intelligence<\/li>\n\n\n\n<li><strong>Molecular Architecture<\/strong>: Next-generation tri-specific T Cell Engager (three-target binding)<\/li>\n\n\n\n<li><strong>Innovation<\/strong>: Represents departure from traditional antibody development models<\/li>\n\n\n\n<li><strong>Development Stage<\/strong>: Preclinical (highest-value preclinical TCE deal from China)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">MTS-128 exemplifies the convergence of artificial intelligence and advanced immunotherapy, leveraging METiS&#8217; NanoForge platform to engineer complex multi-specific molecules with precision targeting capabilities. Unlike conventional bispecific antibodies, tri-specific TCEs can simultaneously engage multiple tumor antigens and T-cell receptors, potentially enhancing tumor selectivity and reducing off-target toxicity.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications-amp-market-context\" class=\"wp-block-heading\">Strategic Implications &amp; Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Strategic Driver<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>China Biotech Internationalization<\/strong><\/td><td>Validates global competitiveness of Chinese AI-driven drug discovery<\/td><\/tr><tr><td><strong>AI Drug Discovery Validation<\/strong><\/td><td>Demonstrates commercial viability of AI-designed therapeutic candidates<\/td><\/tr><tr><td><strong>TCE Market Opportunity<\/strong><\/td><td>Tri-specific TCEs represent next frontier in T-cell engager therapeutics<\/td><\/tr><tr><td><strong>Preclinical Valuation Benchmark<\/strong><\/td><td>Sets new standard for preclinical asset valuations in immuno-oncology<\/td><\/tr><tr><td><strong>Investor Confidence<\/strong><\/td><td>Deerfield backing signals strong institutional validation of asset potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The transaction represents a watershed moment for China&#8217;s biopharmaceutical industry, demonstrating that domestically developed, AI-powered therapeutic platforms can command premium valuations in global markets. The $1.62 billion total deal value significantly exceeds typical preclinical licensing agreements, reflecting both the novelty of the tri-specific TCE approach and confidence in METiS&#8217; NanoForge platform capabilities.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-technology-differentiation\" class=\"wp-block-heading\">Competitive Landscape &amp; Technology Differentiation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Traditional Antibody Development<\/th><th>METiS NanoForge Platform<\/th><\/tr><\/thead><tbody><tr><td><strong>Design Process<\/strong><\/td><td>Empirical screening and optimization<\/td><td>AI-driven molecular engineering<\/td><\/tr><tr><td><strong>Development Timeline<\/strong><\/td><td>12-24 months for lead optimization<\/td><td>Accelerated timeline through computational prediction<\/td><\/tr><tr><td><strong>Molecular Complexity<\/strong><\/td><td>Limited to bispecific formats<\/td><td>Enables tri-specific and higher-order architectures<\/td><\/tr><tr><td><strong>Success Rate<\/strong><\/td><td>Low hit rates in early screening<\/td><td>Enhanced probability through predictive modeling<\/td><\/tr><tr><td><strong>Intellectual Property<\/strong><\/td><td>Incremental improvements<\/td><td>Novel molecular designs with strong patent protection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The tri-specific TCE format addresses key limitations of current T-cell engagers, including tumor antigen escape, cytokine release syndrome, and limited efficacy in solid tumors. By engaging three distinct targets simultaneously, MTS-128 may achieve superior tumor specificity and enhanced T-cell activation compared to existing bispecific approaches.<\/p>\n\n\n\n<h2 id=\"h-financial-impact-amp-forward-outlook\" class=\"wp-block-heading\">Financial Impact &amp; Forward Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The upfront payment of $20 million provides immediate capital infusion for METiS, while the substantial milestone structure aligns payments with clinical and commercial success. The deal validates METiS&#8217; business model of developing AI-designed assets for global partnerships while retaining significant upside through royalties.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This transaction establishes a new benchmark for Chinese biotech companies seeking international partnerships and demonstrates the growing recognition of AI-driven drug discovery as a source of high-value, differentiated therapeutic candidates.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the licensing agreement, clinical development, and commercial potential of MTS-128. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>METiS TechBio (HKG: 7666) announced an exclusive global licensing agreement with Boulevard Bio, a U.S&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4830,4829,4828,2790],"class_list":["post-69112","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-boulevard-bio","tag-hkg-7666","tag-metis-techbio","tag-t-cell-engager"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 \u2013 Largest Preclinical TCE Out-Licensing by Chinese Pharma Company - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"METiS TechBio (HKG: 7666) announced an exclusive global licensing agreement with Boulevard Bio, a U.S. biotechnology company backed by Deerfield Management, granting Boulevard Bio worldwide rights to develop, manufacture, and commercialize MTS-128, METiS&#039; self-developed tri-specific T Cell Engager (TCE) powered by its proprietary AI-driven NanoForge platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69112\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 \u2013 Largest Preclinical TCE Out-Licensing by Chinese Pharma Company\" \/>\n<meta property=\"og:description\" content=\"METiS TechBio (HKG: 7666) announced an exclusive global licensing agreement with Boulevard Bio, a U.S. biotechnology company backed by Deerfield Management, granting Boulevard Bio worldwide rights to develop, manufacture, and commercialize MTS-128, METiS&#039; self-developed tri-specific T Cell Engager (TCE) powered by its proprietary AI-driven NanoForge platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69112\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-30T07:18:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69112#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69112\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 \u2013 Largest Preclinical TCE Out-Licensing by Chinese Pharma Company\",\"datePublished\":\"2026-06-30T07:18:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69112\"},\"wordCount\":573,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Boulevard Bio\",\"HKG: 7666\",\"METiS TechBio\",\"T cell engager\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69112#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69112\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69112\",\"name\":\"METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 \u2013 Largest Preclinical TCE Out-Licensing by Chinese Pharma Company - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-30T07:18:49+00:00\",\"description\":\"METiS TechBio (HKG: 7666) announced an exclusive global licensing agreement with Boulevard Bio, a U.S. biotechnology company backed by Deerfield Management, granting Boulevard Bio worldwide rights to develop, manufacture, and commercialize MTS-128, METiS' self-developed tri-specific T Cell Engager (TCE) powered by its proprietary AI-driven NanoForge platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69112#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69112\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69112#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 \u2013 Largest Preclinical TCE Out-Licensing by Chinese Pharma Company\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 \u2013 Largest Preclinical TCE Out-Licensing by Chinese Pharma Company - Insight, China&#039;s Pharmaceutical Industry","description":"METiS TechBio (HKG: 7666) announced an exclusive global licensing agreement with Boulevard Bio, a U.S. biotechnology company backed by Deerfield Management, granting Boulevard Bio worldwide rights to develop, manufacture, and commercialize MTS-128, METiS' self-developed tri-specific T Cell Engager (TCE) powered by its proprietary AI-driven NanoForge platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69112","og_locale":"en_US","og_type":"article","og_title":"METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 \u2013 Largest Preclinical TCE Out-Licensing by Chinese Pharma Company","og_description":"METiS TechBio (HKG: 7666) announced an exclusive global licensing agreement with Boulevard Bio, a U.S. biotechnology company backed by Deerfield Management, granting Boulevard Bio worldwide rights to develop, manufacture, and commercialize MTS-128, METiS' self-developed tri-specific T Cell Engager (TCE) powered by its proprietary AI-driven NanoForge platform.","og_url":"https:\/\/flcube.com\/?p=69112","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-30T07:18:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69112#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69112"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 \u2013 Largest Preclinical TCE Out-Licensing by Chinese Pharma Company","datePublished":"2026-06-30T07:18:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69112"},"wordCount":573,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Boulevard Bio","HKG: 7666","METiS TechBio","T cell engager"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69112#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69112","url":"https:\/\/flcube.com\/?p=69112","name":"METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 \u2013 Largest Preclinical TCE Out-Licensing by Chinese Pharma Company - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-30T07:18:49+00:00","description":"METiS TechBio (HKG: 7666) announced an exclusive global licensing agreement with Boulevard Bio, a U.S. biotechnology company backed by Deerfield Management, granting Boulevard Bio worldwide rights to develop, manufacture, and commercialize MTS-128, METiS' self-developed tri-specific T Cell Engager (TCE) powered by its proprietary AI-driven NanoForge platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69112#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69112"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69112#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 \u2013 Largest Preclinical TCE Out-Licensing by Chinese Pharma Company"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69112"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69112\/revisions"}],"predecessor-version":[{"id":69113,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69112\/revisions\/69113"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}